Potential treatment option for children with Ewing's sarcoma

July 7, 2015

A research consortium made up of the Virgen del Rocio hospital in Seville, Sant Joan de Deu and the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, has found a new therapeutic alternative for children who suffer from a malignant pediatric tumor bone and soft tissue called Ewing's sarcoma.

Researchers have combined two (Olaparib and Trabectedin), and in animal models have shown that improves the sensitivity of to these drugs, which seems to increase its effect. In fact, they have been observed complete remission of cancer in 100% of cases for a very long time. The study results are published in the journal Oncotarget.

Ewing's sarcoma is the second most common and affects children and youth. Currently, if diagnosed early and there is no metastasis, it can be cured in 80% of cases. But between 25% and 30% of cases are diagnosed when it has metastasized and survival drops to 20%.

"Our results demonstrate that the combination of trabectedin and Olaparib could be a new therapeutic strategy that should be studied in greater depth so that it can benefit patients with this disease in the near future," said Enrique de Alava, director of the Unit Management Clinical Pathology Virgen del Rocio Hospital in Seville and Molecular Pathology group at IBIS.

Efficient combination

It has been observed as Ewing's sarcoma cells need to keep repairing mechanisms of DNA damage in good condition to survive and continue to divide. "Trabectedin, however, causes breaks and abnormal DNA structure of the cell, which induces cell death. And Olaparib works on the same line, blocking the action of a gene (PARP1), whose function is to repair DNA damage when it detects lesions "explained the head of the group IDIBELL Sarcomas, Oscar Martínez Tirado

The combination of both drugs is synergistic and can eliminate the DNA repair system full, obtaining a much more powerful than that achieved with the application of each drug individually antitumor effect.

Explore further: New potential therapeutic strategy against a very aggressive infant bone cancer

More information: Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, Del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. "The PARP inhibitor olaparib enhances the sensitivity of ewing sarcoma to trabectedin." Oncotarget. 2015 [Epub ahead of print]

Related Stories

New potential therapeutic strategy against a very aggressive infant bone cancer

January 29, 2015
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), led by Oscar Martínez Tirado participated in an international study which suggests inhibition of Sirtuin1 (SIRT1) protein as a future treatment option ...

A noncoding RNA promotes pediatric bone cancer

November 17, 2014
Ewing sarcoma is a cancer of bone or its surrounding soft tissue that primarily affects children and young adults. A hallmark of Ewing sarcoma is a translocation event that results in the fusion of an RNA binding protein, ...

Experimental breast cancer drug holds promise in combination therapy for Ewing sarcoma

October 23, 2014
Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. ...

New therapeutic combination to slow resistant sarcomas

July 10, 2014
Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) have been tested in 19 patients a new therapeutic combination to combat resistant ...

Serendipity leads to discovery of adult cancer genes in young-adult Ewing Sarcoma

February 3, 2015
A University of Colorado Cancer Center study published in the journal PLoS One finds alterations in expression of genes PIK3R3 and PTEN, more commonly observed in adult tumors, in the rare, young-adult bone cancer Ewing Sarcoma, ...

Single genetic abnormality accelerates, removes the brakes on Ewing sarcoma tumor growth

December 16, 2014
The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes - both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. ...

Recommended for you

Study suggests colon cancer cells carry bacteria with them when they metastasize

November 24, 2017
(Medical Xpress)—A team of researchers working at Harvard University has found evidence that suggests a certain type of bacteria found in colon cancer tumors makes its way to tumors in other body parts by traveling with ...

Promising new treatment for rare pregnancy cancer leads to remission in patients

November 24, 2017
An immunotherapy drug can be used to cure women of a rare type of cancer arising from pregnancy when existing treatments have failed.

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.